Uncomplicated Urinary Tract Infections in Women

First-Line Treatment Options

The European Association of Urology recommends nitrofurantoin 100 mg twice daily for 5 days as the first-line treatment for uncomplicated cystitis in women, due to its high efficacy and low resistance rates 1
Fosfomycin trometamol 3 g as a single dose is an excellent alternative, offering the advantage of single-dose administration and improved compliance, specifically recommended for women with uncomplicated cystitis 1, 2
Pivmecillinam 400 mg three times daily for 3-5 days is another first-line option, as per European guidelines 1

Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 3 days can be considered as a second-line option, but only if local E. coli resistance is <20% 1
Cephalosporins, such as cefadroxil 500 mg twice daily for 3 days, are acceptable second-line options if local E. coli resistance is <20% 1
Trimethoprim 200 mg twice daily for 5 days is another alternative, with the same resistance considerations 1

The European Urology guidelines recommend confirming symptomatic UTI and starting empiric therapy immediately, without delaying treatment for culture results in uncomplicated cases 1, 2
Nitrofurantoin 100 mg BID for 5 days is recommended as first-line therapy, or fosfomycin 3 g once if single-dose preferred 1, 2
If symptoms persist, reassess and obtain urine culture and susceptibility testing, and retreat with a different agent for 7 days 1

The European Association of Urology recommends avoiding nitrofurantoin in patients with creatinine clearance <30 mL/min, due to inadequate renal function for therapeutic urinary concentrations 2
Fluoroquinolones should be reserved for complicated infections or pyelonephritis, not uncomplicated cystitis, to preserve their effectiveness and minimize resistance 3
Asymptomatic bacteriuria should not be treated in non-pregnant women, and surveillance cultures should not be obtained in asymptomatic patients 2
For recurrent UTIs, consider non-antibiotic preventive strategies, including vaginal estrogen in postmenopausal women, and reserve continuous antibiotic prophylaxis only after non-antimicrobial interventions have failed 1, 3